STATIN THERAPY IN PATIENTS WITH
DIABETES AND HEPATITIS C
EMILIA RUSU1,2, MARIANA JINGA2,3*, FLORIN RUSU3, COZIANA
CIURTIN4, GEORGIANA ENACHE5, ANDREEA DRAGOMIR2,
VASILICA CRISTESCU1, VICTOR STOICA2, ADRIAN COSTACHE2,
DAN CHETA1, GABRIELA RADULIAN1,2
1“Prof. N. Paulescu” Diabetes, Nutrition and Metabolic Diseases
Institute, Bucharest
2“Carol Davila” University of Medicine, Bucharest
3“Carol Davila” Emergency Military Hospital, Bucharest
4Lister Hospital, London
5County Emergency Hospital Calarasi, Calarasi
*corresponding author: mariana_jinga@yahoo.com
Download Full Article

Abstract:

The objective of this study was to determine the effects of statin therapy
(atorvastatin) on serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C (CHC).
A number of 77 patients with T2DM and CHC were selected, treated with
atorvastatin, 20 mg, for 6 months, who underwent anthropometric measurements and biochemical tests (including fasting serum glucose, lipid profile, liver profile, cytokines profile) at baseline, after 1 month (clinical and biochemical profile for safety) and after 6 months of treatment.

Top